Allogeneic Hematopoietic Stem Cell Transplantation With Reduced Intensity

Status Terminated

Clinical Trial Summary

This is study is for patients that have been diagnosed with high-risk hematological malignancies. The main purpose of this study is to confirm previously published results of stem cell transplantation with reduced intensity pre-transplant conditioning. Patients will be assigned to 1 of 3 regimens depending on the patient's diagnosis. Participants will be followed by the transplant team for the remainder of the patient's life. Patient's will visit MUSC daily, then visits will be reduced to frequent visits for up to 6 months. After 6 months, the visits will be reduced more depending on the patient's condition.

Clinical Trial Description

n/a

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT01139164
Study type	Interventional
Source	Medical University of South Carolina
Contact
Status	Terminated
Phase	Phase 2
Start date	June 2010
Completion date	December 2015

View Details

See also
Status	Clinical Trial	Phase
Terminated	`NCT03248479` - Magrolimab Monotherapy or Magrolimab in Combination With Azacitidine in Participants With Hematological Malignancies	Phase 1
Recruiting	`NCT05454241` - CD7 CAR-T for Patients With r/r CD7+ Hematologic Malignancies	Phase 2
Recruiting	`NCT06041815` - Correlation Between Gut Microbiota and Clinical Response to CAR-T Treatment for Hematological Malignancies
Active, not recruiting	`NCT05005442` - A Study of Pembrolizumab/Vibostolimab (MK-7684A) in Relapsed/Refractory Hematological Malignancies (MK-7684A-004, KEYVIBE-004)	Phase 2
Recruiting	`NCT02300571` - Observational Study of the Combination of Post-transplant High Dose Cyclophosphamide, Tacrolimus and Mycophenolate Mofetil for the Prevention of Acute Graft-versus-Host Disease in Patients Eligible to Allogeneic Hematopoietic Stem Cell Transplant	N/A
Active, not recruiting	`NCT01428973` - Minitransplants With HLA-matched Donors : Comparison Between 2 GVHD Prophylaxis Regimens	Phase 2
Completed	`NCT00379587` - Rituximab for Prevention of Chronic GVHD	Phase 1/Phase 2
Terminated	`NCT00506948` - Thymoglobulin, Sirolimus and Mycophenolate Mofetil for Prevention of Acute Graft-Versus-Host Disease (GVHD)	Phase 2
Completed	`NCT01162096` - Reduced Intensity Haploidentical Transplant for Hematological Malignancies	Phase 1/Phase 2
Active, not recruiting	`NCT04557098` - A Study of Teclistamab in Participants With Relapsed or Refractory Multiple Myeloma	Phase 2
Recruiting	`NCT04283097` - Safety, Tolerability and Pharmacokinetics Study of KPG-818 in Hematological Malignancies Subjects	Phase 1
Completed	`NCT03067155` - CMV Specific T Cell Therapy After Allogeneic Stem Cell Transplantation.	Phase 2
Completed	`NCT01725555` - A Study to Assess the Effect of Food on the Bioavailability of the IGF-1R Inhibitor AXL1717 in Patients With Advanced Malignant Tumors	Phase 1
Completed	`NCT00438178` - Safety and Efficacy of Obatoclax Mesylate (GX15-070MS) for the Treatment of Hematological Malignancies	Phase 1
Completed	`NCT03711604` - Compassionate Use Study of Tenalisib (RP6530)	Phase 1/Phase 2
Withdrawn	`NCT01168882` - Safety and Tolerability of RGB-286638 in Patients With Selected, Relapsed or Refractory Hematological Malignancies	Phase 1
Completed	`NCT01246206` - Tacrolimus and Thymoglobulin, as GvHD Prophylaxis in Patients Undergoing Related Donor HCT	Phase 2
Completed	`NCT01172132` - The Use of Intensive Care in Critically Ill Cancer Haematological Patients: "TRIAL-OH"	N/A
Completed	`NCT00506402` - A Phase 1 Study of MKC-1 in Patients With Refractory Hematologic Malignancies	Phase 1
Active, not recruiting	`NCT00163644` - RCT to Investigate Whether an Exercise Programme Improves the Physical Performance and QOL After BMT	N/A

Allogeneic Hematopoietic Stem Cell Transplantation With Reduced Intensity Pre-transplant Conditioning for the Treatment of High-risk Hematological Malignancies (V3)

Clinical Trial Summary

Clinical Trial Description

Study Design

Related Conditions & MeSH terms